on September 25, 2008
Published online before print September 25, 2008, doi: 10.1161/ATVBAHA.108.175687
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Submitted on June 4, 2008
Accepted on September 12, 2008
Pioglitazone Inhibits the Expression of Inflammatory Cytokines From Both Monocytes and Lymphocytes in Patients With Impaired Glucose Tolerance
Wei-Yang Zhang ;
From the Department of Medicine, Section of Endocrinology, Phoenix Veteran's Affairs Health Care System, Ariz.
* To whom correspondence should be addressed. E-mail: peter.reaven{at}va.gov.
Objective—The current study determines whether pioglitazone (PIO) therapy reduces both monocyte and lymphocyte inflammatory activity and their ability to induce inflammation in other tissues.
Methods and Results—Monocyte and lymphocyte gene and protein expression of interleukin (IL)-6 were first shown to be greater in subjects with impaired glucose tolerance (IGT) than in subjects with normal glucose tolerance. Sixty-six IGT subjects were then randomized to 5 months of placebo or PIO therapy. After receiving PIO, subjects had lower triglycerides and higher HDL cholesterol (P<0.05) than did subjects receiving placebo. Monocyte gene and protein expression of IL-1
, IL-6, and IL-8 (and IL-2, IL-6 and IL-8 from lymphocytes) was significantly lower after PIO therapy in the resting state, as well as after lipopolysaccharide (LPS) stimulation (P<0.05 for all). Moreover, IL-6, IL-8, and MCP-1 gene expression were decreased by nearly 50% in human adipocytes exposed to conditioned media from monocytes or lymphocytes from PIO treated subjects.
Conclusion—These results demonstrate that PIO therapy in IGT can reduce proinflammatory gene and protein expression from both monocytes and lymphocytes. This intervention also reduces the inflammatory cross-talk between these immune cells and adipose tissue, which could in turn contribute to the metabolic improvements resulting from PIO therapy.
Key words: thiazolidinediones • cytokine • monocytes • lymphocytes • adipose tissue
This article has been cited by other articles:
 |
|
 |
|
  M. R. Dasu, S. Park, S. Devaraj, and I. Jialal Pioglitazone Inhibits Toll-Like Receptor Expression and Activity in Human Monocytes and db/db Mice Endocrinology, August 1, 2009; 150(8): 3457 - 3464. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H. Nakaya, B. D. Summers, A. C. Nicholson, A. M. Gotto Jr., D. P. Hajjar, and J. Han Atherosclerosis in LDLR-Knockout Mice Is Inhibited, but Not Reversed, by the PPAR{gamma} Ligand Pioglitazone Am. J. Pathol., June 1, 2009; 174(6): 2007 - 2014. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. A. Permana, W. Zhang, M. Wabitsch, P. Fischer-Posovszky, W. C. Duckworth, and P. D. Reaven Pioglitazone reduces inflammatory responses of human adipocytes to factors secreted by monocytes/macrophages Am J Physiol Endocrinol Metab, May 1, 2009; 296(5): E1076 - E1084. [Abstract] [Full Text] [PDF]
|
|